Cardiac Safety London

Event Date:
Wednesday 20th May 2020 - 10am – 3.30pm BST
Location:
Online Event
View ProgramView Program

To help to enrich and speed up your drug development programs, join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss the latest state of the art methods in early phase clinical research. The event will provide insight to enable better patient outcomes, efficiency, and cost-effectiveness in global drug development.

The 20th of May also is World Clinical Trials Day celebrating the anniversary of the first clinical trial by James Lind in 1747 into the causes of scurvy on board the HMS Salisbury. On this occasion, we will also showcase work from our Research Institute, our not-for-profit affiliate dedicated to academic research.


Programme

  • Updates on the CSRC white paper on cardiac safety assessments of anti-diabetic medicines
  • Waveform analysis and measurements of QT subintervals
  • Repolarization disturbances in type 1 long QT syndrome patients
  • Cardiac safety embedded in adaptive clinical trials
  • Sex differences in cardiac risk
  • Regulatory updates in drug development
  • Preclinical science and models in cardiac safety assessments
  • Modelling and statistics of pharmacodynamic markers

Click here to view the agenda

This is an online event, to express an interest in this event or to learn more details please contact Jack Wilmott on j.wilmott@richmondpharmacology.com

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more